Shares in Proteome were trading up 12% at
The study was published in 'Alzheimers & Dementia:
Using data from three international studies, it took blood samples from a total of 1,148 individuals and analysed them for 26 proteins that had previously shown a connection to Alzheimer's.
From this study, the company identified 10 proteins capable of predicting whether patients with mild cognitive impairment would develop Alzheimer's within a year, which it said has an accuracy of 87%.
Proteome said that it was selecting commercial partners to combine these protein biomarkers in a blood test for the global market.
The company said the study was a "major advance" in developing a blood test for the disease, and such a test would be easier and less expensive than using brain imaging or cerebrospinal fluid.
Most Popular Stories
- Americans Still Pessimistic Despite Economic Growth
- GE Capital and Petters-Related Fund in Legal Battle
- Combating Online Abuse Not Easy for Gamers
- Feds Want Nuclear Waste Train, but Nowhere to Go
- California Conservation Conundrum: Water Use Varies Greatly Across State
- Even With Surly 2014 Electorate, It's 'Still an Incumbent's World'
- Detroit Raced Toward this Week's Bankruptcy Trial
- New Hershey's Logo Revealed
- California Passes First US Statewide Bag Ban
- Obama on Labor Day: Don't Take Rights for Granted